These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38334638)

  • 1. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
    Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
    Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
    Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.
    Kellner C; Lutz S; Oberg HH; Wesch D; Otte A; Diemer KJ; Wilcken H; Bauerschlag D; Glüer CC; Wichmann C; Kabelitz D; Leusen JHW; Klausz K; Humpe A; Gramatzki M; Peipp M
    Biol Chem; 2022 Apr; 403(5-6):545-556. PubMed ID: 34717050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
    Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
    Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
    Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
    Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
    Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
    Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
    Guo C; Dong M; Wang X; Yu J; Jin X; Cheng S; Cui F; Qian Y; Bao Q; Zhi L; Niu Z; Li M; Zhu W
    Biochem Biophys Res Commun; 2024 May; 710():149918. PubMed ID: 38598902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
    Lazarova M; Wels WS; Steinle A
    Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.
    Herault A; Mak J; de la Cruz-Chuh J; Dillon MA; Ellerman D; Go M; Cosino E; Clark R; Carson E; Yeung S; Pichery M; Gador M; Chiang EY; Wu J; Liang Y; Modrusan Z; Gampa G; Sudhamsu J; Kemball CC; Cheung V; Nguyen TTT; Seshasayee D; Piskol R; Totpal K; Yu SF; Lee G; Kozak KR; Spiess C; Walsh KB
    Cancer Immunol Immunother; 2024 Aug; 73(10):209. PubMed ID: 39112670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications.
    Song AY; Kim H; Kim JM; Hwang SH; Ko DH; Kim HS
    ACS Appl Mater Interfaces; 2021 Sep; 13(36):42370-42381. PubMed ID: 34486371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.